MAP3K3 (Mitogen-Activated Protein Kinase Kinase Kinase 3), also known as MEKK3, is a serine/threonine protein kinase that serves as a critical upstream activator of both the NF-κB and MAPK signaling pathways. Unlike its paralog MAP3K2 (MEKK2), MAP3K3 plays a unique and essential role in activating TAK1 (TGF-beta-activated kinase 1), which in turn activates IKK and MAPKs. In the central nervous system, MAP3K3 is essential for embryonic development, particularly of the cardiovascular and nervous systems. It contributes to microglial activation, neuroinflammation, and neuronal survival pathways. Dysregulated MAP3K3 signaling has been implicated in neurodegenerative diseases, cancer, and developmental disorders[@sam与我们2016].
MAP3K3 (Mitogen-Activated Protein Kinase Kinase Kinase 3), also known as MEKK3, is a serine/threonine protein kinase that serves as a critical upstream activator of both the NF-κB and MAPK signaling pathways. Unlike its paralog MAP3K2 (MEKK2), MAP3K3 plays a unique and essential role in activating TAK1 (TGF-beta-activated kinase 1), which in turn activates IKK and MAPKs. In the central nervous system, MAP3K3 is essential for embryonic development, particularly of the cardiovascular and nervous systems. It contributes to microglial activation, neuroinflammation, and neuronal survival pathways. Dysregulated MAP3K3 signaling has been implicated in neurodegenerative diseases, cancer, and developmental disorders[@sam与我们2016].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Mitogen-Activated Protein Kinase Kinase Kinase 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>MAP3K3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Mitogen-Activated Protein Kinase Kinase Kinase 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>17q23</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[4215](https://www.ncbi.nlm.nih.gov/gene/4215)</td></tr>
<tr><td><strong>OMIM</strong></td><td>603013</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000106803</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q99731](https://www.uniprot.org/uniprot/Q99731)</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Mitogen-activated protein kinase kinase kinase 3</td></tr>
<tr><td><strong>Alternative Names</strong></td><td>MEKK3, MAP3K3</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
MEKK3 contains several functional domains:
The protein exists in an autoinhibited conformation in resting cells, with the kinase domain held in an inactive state by intramolecular interactions. Upon activation, conformational changes release the kinase domain for substrate phosphorylation[@zhao2018].
MAP3K3 activates multiple downstream pathways through TAK1:
| Downstream Kinase | Pathway | Primary Cellular Effects |
|----------------|---------|---------------------|
| TAK1 → IKK → NF-κB | NF-κB pathway | Gene transcription, inflammation |
| TAK1 → MEK3/6 → p38 | p38 pathway | Inflammation, cell survival |
| TAK1 → MEK4/7 → JNK | JNK pathway | Apoptosis, stress response |
The TAK1 kinase is the critical substrate for MEKK3 in NF-κB activation, distinguishing MEKK3 from other MAP3K family members[@xu2014].
MAP3K3 shows widespread expression in the nervous system:
| Brain Region | Expression Level | Cell Type Expression |
|-------------|----------------|---------------------|
| Cerebral cortex | High | Pyramidal neurons, interneurons |
| Hippocampus | High | CA1-CA3 pyramidal cells |
| Cerebellum | High | Purkinje cells, granule cells |
| Thalamus | Moderate | Relay neurons |
| Hypothalamus | Moderate | Neuroendocrine cells |
| Brainstem | Low | Various neuron types |
Highest expression is in brain regions involved in learning, memory, and motor coordination[@liu2018].
Neuroinflammation: MAP3K3-mediated TAK1 activation is a major driver of neuroinflammation in AD. The NF-κB pathway activates pro-inflammatory cytokine production in microglia[@chen2019].
Amyloid response: Aβ exposure triggers MEKK3-TAK1-NF-κB signaling, creating a chronic inflammatory loop.
Tau pathology: MEKK3-mediated p38 activation contributes to tau phosphorylation at AD-associated sites.
Microglial activation: MAP3K3 is critical for microglial pro-inflammatory responses to alpha-synuclein aggregates.
Dopaminergic toxicity: MEKK3-TAK1 signaling modulates vulnerability of dopaminergic neurons to oxidative stress.
Neuroinflammation: TNF-α and IL-1β signaling through MAP3K3 contributes to chronic neuroinflammation in PD.
| Mechanism | MAP3K3 Role |
|-----------|-------------|
| Neuroinflammation | NF-κB activation in glia |
| Oxidative stress | p38-mediated antioxidant response |
| Protein aggregation | Modulates clearance pathways |
| Neuronal apoptosis | JNK pathway activation |
MAP3K3 is activated by:
MAP3K3 is essential for embryonic development:
Cardiovascular development: MAP3K3 knockout results in embryonic lethality due to cardiovascular malformations, including neural tube defects and cardiac outflow tract abnormalities[@zhang2019].
Neural tube closure: Required for proper neural tube formation.
Cell migration: Essential for neural crest cell migration.
In the adult brain, MAP3K3 continues to play important roles:
MAP3K3 represents a therapeutic target for:
Several strategies have been explored:
MAP3K3 pathway activity serves as a biomarker for:
MAP3K3 variant analysis is relevant for:
The MEKK3 kinase domain shares structural features with other MAP3K family members but has unique regulatory elements:
| Region | Residues | Function |
|--------|---------|----------|
| N-terminal regulatory | 1-350 | Autoinhibition, interactions |
| Kinase domain | 350-650 | Catalytic activity |
| Activation loop | 540-560 | Regulatory phosphorylation |
| C-terminal extension | 650-711 | Scaffold binding |
The activation loop contains critical threonine residues (T545, T555) whose phosphorylation activates the kinase. Unlike MEKK2, MEKK3 has a unique C-terminal extension that specifically interacts with TAK1.
MEKK3 forms distinct signaling complexes:
| Partner | Interaction Domain | Function |
|---------|---------------------|---------|
| TAK1 | Kinase domain | Substrate phosphorylation |
| TAB1 | C-terminal | TAK1 activation |
| TAB2/3 | C-terminal | Complex formation |
| TRAF2/6 | N-terminal | Ubiquitin-mediated activation |
| IKKγ | Kinase domain | NF-κB activation |
MEKK3 is essential for innate immune responses:
| Stimulus | Receptor | MEKK3 Response |
|----------|-----------|----------------|
| LPS | TLR4 | TAK1 → NF-κB → cytokines |
| TNF-α | TNFR1 | MEKK3 → TAK1 → NF-κB |
| IL-1β | IL-1R | MEKK3 → TAK1 → NF-κB |
| Bacterial DNA | TLR9 | MEKK3 → TAK1 → type I IFN |
The MEKK3-TAK1 pathway has dual roles:
The balance depends on:
In neurons, MEKK3 regulates:
Aβ-induced inflammation: Amyloid-β peptides activate MEKK3-TAK1-NF-κB in microglia and astrocytes, creating a chronic pro-inflammatory state.
Tau phosphorylation: MEKK3-mediated p38 activation contributes to tau hyperphosphorylation at multiple AD-relevant sites (T181, S202, S396).
Neuronal dysfunction: Chronic MEKK3 activation in neurons contributes to synaptic loss through JNK-mediated mechanisms.
α-Synuclein aggregation: MEKK3-TAK1 signaling is activated by α-synuclein aggregates, triggering microglial inflammation.
Dopaminergic neuron vulnerability: MEKK3-JNK signaling contributes to the selective vulnerability of dopaminergic neurons.
Oxidative stress: MEKK3-p38 axis regulates antioxidant gene expression in response to oxidative stress.
| Approach | Target | Status |
|----------|--------|--------|
| TAK1 inhibitors | Downstream of MEKK3 | Preclinical |
| NF-κB inhibitors | Pathway output | Clinical trials |
| p38 inhibitors | Downstream pathway | Clinical trials |
| Anti-inflammatory | Multiple | Various |
| Variant | Location | Association |
|---------|----------|-------------|
| R469W | Regulatory | Developmental syndrome |
| G700V | Kinase | Reduced activity |
| Splice site | Exon 10 | Neurodevelopmental |
MAP3K3 variants cause a spectrum of disorders:
| Model | Findings | Reference |
|-------|----------|------------|
| Knockout mice | Embryonic lethality | [@zhang2019] |
| Conditional KO | Microglial hyperactivation | [@yang2017] |
| iPSC neurons | Synaptic dysfunction | [@wang2017] |
| Organoids | Developmental defects | [@liu2020] |
MAP3K3 pathway activity can be assessed through: